ALEMG.PA Euromedis Groupe SA

Healthcare Health Care Equipment & Supplies Euronext Paris
5.45 EUR
Close of Nov 7, 2026
3.85 6.15
Market cap
EUR 15.6M
P/E
-
P/B
0.95x
ROE
76.9%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALEMG.PA undervalued?

Graham number

The Graham number of Euromedis Groupe SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Euromedis Groupe SA fundamental analysis

3 of 11 checks passed

ROE 0/2

Negative ROE (-15.73%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-10.4%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (0.42x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a low debt to equity ratio (37%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Graham Number 1/1

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

Dividend Growth 0/2

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Dividend 0/2

The company's lack of dividends in the past three years may concern investors seeking regular income.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (-193) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Euromedis Groupe SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Euromedis Groupe SA

Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, micro perfusionists; infusion and transfusion services, catheters, accessories, and waste collectors; disinfection, hygiene, and surface protection…

Full company profile